Navigation Links
Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
Date:9/10/2008

Non-stimulant drug addresses wide range of symptoms of ADHD

DURHAM, N.C., Sept. 10 /PRNewswire/ -- A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals.

The study showed that the new drug, Clonicel, achieved statistically significant improvement over placebo in reducing an aggregate of 18 ADHD symptoms listed by the American Psychiatric Association and used by physicians to diagnose and classify the condition.

"This is the first study to validate the potential for a long-acting version of clonidine -- a widely used hypertension drug -- as a safe and effective treatment for ADHD," said Moise Khayrallah, Ph.D., CEO of Addrenex Pharmaceuticals, a small Durham start-up that initiated and coordinated the multicenter trial.

Previous studies of clonidine have indicated that the drug diminishes select symptoms of ADHD, but these studies have been small and inconclusive, Khayrallah said. Moreover, clonidine carries bothersome side effects that have limited its use, including a peak of drowsiness when the drug is absorbed and a subsequent rebound of symptoms when drug levels subside.

Addrenex scientists developed Clonicel to reduce these side effects and treat specific ADHD symptoms that may occur when the body's adrenergic system is in overdrive, producing excessive levels of the stress hormone adrenaline. Such symptoms include emotional outbursts, mood swings, insomnia and hyperreactivity to stress.

"We conducted a well-powered, randomized clinical trial to demonstrate that Clonicel may be effective on its own in treating a multitude of ADHD symptoms, with a favorable side effect profile," said Khayrallah. "We're very excited with the positive data we obtained, and we intend for this study to serve as part of the basis for review and approval by the FDA, hopefully by next year."

The study showed that Clonicel was statistically superior to placebo on the primary endpoint, the ADHD Rating Scale of 18 symptoms. Clonicel was also statistically superior to placebo on several secondary scales completed by clinicians and parents, including a scale that assesses adrenergic dysregulation. The scale was designed by Joseph Horacek, M.D., a Charlotte neuropsychiatrist and cofounder of Addrenex. Side effects were generally mild to moderate in severity, and no serious adverse events were reported in the study.

A total of 228 children between the ages of 6 and 17 with a diagnosis of ADHD participated in the randomized, double-blind, placebo-controlled trial that compared two doses of Clonicel, 0.2 mg per day and 0.4 mg per day, with placebo. Children received either study medication or placebo for eight weeks at one of 13 study centers nationwide.

If Clonicel is approved by the Food and Drug Administration, the new drug will be marketed by Sciele Pharma under an agreement signed with Addrenex in July 2007.

The introduction of Clonicel into the ADHD market would fill a void that currently exists in the treatment of ADHD, Khayrallah said. While stimulants play an important role in treating ADHD, they do not address all of the symptoms associated with the disorder and may result in unacceptable side effects in some patients.

Because Clonicel targets receptors within the body's stress response center -- the adrenergic system -- it may be more effective in alleviating lesser-known symptoms that accompany ADHD, such as emotional outbursts, mood swings, irritability and hyperreactivity to stress, Horacek said.

"We believe that Clonicel is normalizing the excess of the adrenergic hormones that contribute to many of the symptoms of ADHD," said Horacek.

Stress hormones produce a rapid heart rate, elevated blood pressure, sweating, temperature increases, heightened anxiety, stress and fear, he said. Scientists have implicated an excessive stress response to a wide array of disorders, from ADHD and Tourette's syndrome to post-traumatic stress disorder and migraines.

Addrenex is currently developing a cadre of drugs focused on treating these and other conditions arising from adrenergic excess, including hypertension, menopausal flushing, pain and sleep disturbance. By mining a library of 400 adrenergic compounds at the University of Nebraska Medical Center, Addrenex scientists have already identified one new drug candidate, a compound code named ADX415, to treat hypertension and other conditions.

"With the extremely positive data from our first study, we are well under way toward our goal of regulating adrenergic excess and helping to ameliorate medical conditions that arise from this physiologic imbalance," said Khayrallah.

The company is also midway through a second ADHD clinical trial testing the effects of Clonicel together with stimulants. The goal is to determine if the two treatments together alleviate a broader range of symptoms than either drug alone.


'/>"/>
SOURCE Addrenex
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
2. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
9. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):